benzatropine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	333	86-13-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cogentin benztropine mesilate benzatropine benztropine tropine benzohydryl ether benztropine mesylate	A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. Molecular weight: 307.44 Formula: C21H25NO CLOGP: 3.52 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.41 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cogentin
benztropine mesilate
benzatropine
benztropine
tropine benzohydryl ether
benztropine mesylate

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Molecular weight: 307.44
Formula: C21H25NO
CLOGP: 3.52
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -5.41
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O
2	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	29 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 5, 1954	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Granulocytopenia	344.12	18.05	96	9452	5464	53334054
Completed suicide	291.97	18.05	222	9326	137979	53201539
Tardive dyskinesia	180.29	18.05	64	9484	8006	53331512
Schizophrenia	175.94	18.05	67	9481	10212	53329306
Psychotic disorder	160.27	18.05	81	9467	24304	53315214
Toxicity to various agents	128.15	18.05	176	9372	219422	53120096
Neuroleptic malignant syndrome	125.51	18.05	55	9493	11978	53327540
Extrapyramidal disorder	114.35	18.05	52	9496	12350	53327168
Paranoia	108.82	18.05	49	9499	11375	53328143
Hallucination, auditory	107.40	18.05	49	9499	11724	53327794
Sedation	72.06	18.05	52	9496	29623	53309895
Dystonia	67.69	18.05	37	9511	12984	53326534
Oculogyric crisis	66.66	18.05	20	9528	1468	53338050
Agitation	66.03	18.05	66	9482	58560	53280958
Muscle rigidity	65.36	18.05	34	9514	10807	53328711
Blood prolactin increased	58.60	18.05	22	9526	3217	53336301
Tremor	54.73	18.05	88	9460	125648	53213870
Catatonia	53.88	18.05	22	9526	4018	53335500
Schizoaffective disorder	51.40	18.05	18	9530	2159	53337359
Ileus paralytic	51.08	18.05	22	9526	4589	53334929
Suicidal ideation	50.28	18.05	58	9490	60453	53279065
Dyskinesia	49.68	18.05	43	9505	31790	53307728
Clonus	49.27	18.05	21	9527	4270	53335248
Aggression	47.85	18.05	37	9511	23366	53316152
Akathisia	46.34	18.05	25	9523	8546	53330972
Delusion	46.06	18.05	28	9520	11981	53327537
Leukopenia	45.88	18.05	61	9487	73402	53266116
Hyperreflexia	44.35	18.05	21	9527	5459	53334059
Myocarditis	43.84	18.05	24	9524	8444	53331074
Drooling	43.05	18.05	18	9530	3490	53336028
Galactorrhoea	40.80	18.05	18	9530	3977	53335541
Cardiac arrest	37.28	18.05	63	9485	93604	53245914
Abnormal behaviour	37.11	18.05	31	9517	21835	53317683
Salivary hypersecretion	36.83	18.05	20	9528	6923	53332595
Treatment noncompliance	36.82	18.05	37	9511	32998	53306520
Amaurosis	36.35	18.05	10	9538	538	53338980
Hyperthermia	35.51	18.05	21	9527	8548	53330970
Confusional state	34.46	18.05	94	9454	194127	53145391
Haemoglobin urine	33.53	18.05	7	9541	113	53339405
Drug interaction	32.96	18.05	100	9448	219229	53120289
Hallucination	32.52	18.05	44	9504	53794	53285724
Encephalitis autoimmune	31.69	18.05	11	9537	1285	53338233
Joint swelling	31.16	18.05	3	9545	234635	53104883
Mydriasis	30.14	18.05	21	9527	11305	53328213
Amenorrhoea	28.85	18.05	19	9529	9330	53330188
Arthralgia	28.84	18.05	22	9526	439761	52899757
Torsade de pointes	27.54	18.05	21	9527	12984	53326534
Psychiatric decompensation	27.39	18.05	10	9538	1352	53338166
Dysarthria	27.35	18.05	35	9513	40533	53298985
Parkinsonism	27.05	18.05	18	9530	8995	53330523
Cardio-respiratory arrest	26.73	18.05	42	9506	58716	53280802
Electrocardiogram QT prolonged	26.61	18.05	41	9507	56362	53283156
Toxic encephalopathy	25.81	18.05	15	9533	5912	53333606
Diabetes mellitus	25.17	18.05	39	9509	53860	53285658
Mental disorder	24.80	18.05	26	9522	24350	53315168
Hyperprolactinaemia	24.68	18.05	12	9536	3303	53336215
Cognitive disorder	24.65	18.05	35	9513	44743	53294775
Suspected suicide	24.34	18.05	13	9535	4355	53335163
Lipids decreased	24.29	18.05	4	9544	15	53339503
Facial paralysis	24.07	18.05	20	9528	13973	53325545
Red blood cells urine	23.95	18.05	7	9541	469	53339049
Diarrhoea	22.68	18.05	49	9499	625497	52714021
Eosinophil count abnormal	22.55	18.05	7	9541	576	53338942
Mental status changes	21.88	18.05	31	9517	39540	53299978
Restlessness	21.78	18.05	26	9522	28061	53311457
Schizoaffective disorder bipolar type	21.47	18.05	5	9543	136	53339382
Hypersensitivity	20.73	18.05	6	9542	210659	53128859
Pain	20.57	18.05	47	9501	588351	52751167
Mania	20.54	18.05	17	9531	11812	53327706
Abdominal discomfort	20.50	18.05	7	9541	221055	53118463
Flat affect	19.93	18.05	8	9540	1397	53338121
Bipolar disorder	19.87	18.05	14	9534	7672	53331846
Areflexia	19.67	18.05	10	9538	3026	53336492
Pneumonia aspiration	19.15	18.05	27	9521	34274	53305244
Screaming	18.95	18.05	10	9538	3267	53336251

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Granulocytopenia	529.11	18.88	161	11125	6354	32495886
Completed suicide	219.76	18.88	211	11075	92306	32409934
Tardive dyskinesia	183.86	18.88	70	11216	5461	32496779
Neuroleptic malignant syndrome	172.68	18.88	95	11191	17400	32484840
Extrapyramidal disorder	158.54	18.88	79	11207	11816	32490424
Myocarditis	154.55	18.88	77	11209	11513	32490727
Psychotic disorder	146.03	18.88	94	11192	22926	32479314
Toxicity to various agents	130.04	18.88	226	11060	177815	32324425
Schizophrenia	123.34	18.88	63	11223	9921	32492319
Agitation	98.48	18.88	110	11176	57126	32445114
Hallucination, auditory	96.05	18.88	54	11232	10296	32491944
Dystonia	94.74	18.88	54	11232	10569	32491671
Akathisia	85.80	18.88	44	11242	6981	32495259
Tremor	77.99	18.88	117	11169	81160	32421080
Sedation	71.74	18.88	56	11230	18470	32483770
Cogwheel rigidity	70.96	18.88	24	11262	1326	32500914
Drooling	69.17	18.88	30	11256	3267	32498973
Galactorrhoea	65.18	18.88	17	11269	376	32501864
Dystonic tremor	65.06	18.88	15	11271	194	32502046
Device leakage	62.35	18.88	31	11255	4605	32497635
Abnormal behaviour	60.02	18.88	59	11227	26407	32475833
Hyperprolactinaemia	59.83	18.88	21	11265	1297	32500943
Leukopenia	58.27	18.88	87	11199	60035	32442205
Muscle rigidity	54.91	18.88	39	11247	11147	32491093
Paranoia	53.82	18.88	38	11248	10761	32491479
Treatment noncompliance	53.23	18.88	56	11230	27146	32475094
Drug abuse	52.10	18.88	97	11189	80146	32422094
Aggression	51.70	18.88	66	11220	39323	32462917
Syringe issue	50.46	18.88	25	11261	3686	32498554
Parkinsonism	49.52	18.88	32	11254	7837	32494403
Schizoaffective disorder	48.71	18.88	18	11268	1290	32500950
Anticholinergic syndrome	47.30	18.88	16	11270	884	32501356
Restlessness	44.76	18.88	49	11237	24832	32477408
Drug interaction	44.41	18.88	171	11115	218014	32284226
Product dose omission issue	44.37	18.88	105	11181	102470	32399770
Inappropriate schedule of product administration	43.93	18.88	66	11220	45759	32456481
Priapism	43.49	18.88	25	11261	4966	32497274
Antipsychotic drug level increased	42.68	18.88	22	11264	3524	32498716
Catatonia	42.14	18.88	24	11262	4684	32497556
Blood prolactin increased	38.29	18.88	16	11270	1589	32500651
Delusion	36.97	18.88	33	11253	13075	32489165
Dyskinesia	36.54	18.88	43	11243	23560	32478680
Mental status changes	36.43	18.88	55	11231	38282	32463958
Suicidal ideation	35.29	18.88	54	11232	38029	32464211
Drug level increased	35.17	18.88	39	11247	20041	32482199
Agranulocytosis	35.07	18.88	42	11244	23435	32478805
Eosinophilic pleural effusion	32.48	18.88	9	11277	252	32501988
Blood creatine phosphokinase increased	32.05	18.88	57	11229	45419	32456821
Sinus tachycardia	30.69	18.88	33	11253	16381	32485859
Delirium	29.50	18.88	54	11232	43992	32458248
Lethargy	29.47	18.88	52	11234	41176	32461064
Homicidal ideation	27.64	18.88	15	11271	2665	32499575
Head titubation	27.47	18.88	8	11278	269	32501971
Musculoskeletal stiffness	27.39	18.88	49	11237	39215	32463025
Diarrhoea	26.84	18.88	54	11232	364748	32137492
Blood pH decreased	26.72	18.88	14	11272	2319	32499921
Mania	26.67	18.88	24	11262	9608	32492632
Blood triglycerides increased	26.65	18.88	29	11257	14590	32487650
Oculogyric crisis	26.51	18.88	12	11274	1445	32500795
Overdose	26.27	18.88	78	11208	86999	32415241
Febrile neutropenia	25.98	18.88	5	11281	119561	32382679
Needle issue	25.47	18.88	17	11269	4392	32497848
Bipolar disorder	24.86	18.88	16	11270	3890	32498350
Antipsychotic drug level decreased	24.68	18.88	10	11276	918	32501322
Parasomnia	24.57	18.88	8	11278	392	32501848
Type 2 diabetes mellitus	24.07	18.88	28	11258	15144	32487096
Device malfunction	24	18.88	22	11264	9017	32493223
Weight increased	23.42	18.88	73	11213	83590	32418650
Haemophagocytic lymphohistiocytosis	21.56	18.88	23	11263	11312	32490928
Gynaecomastia	20.61	18.88	20	11266	8799	32493441
Globulins decreased	20.51	18.88	6	11280	205	32502035
Troponin increased	20.39	18.88	21	11265	9921	32492319
Salivary hypersecretion	20.15	18.88	19	11267	8069	32494171
Somnolence	19.93	18.88	80	11206	103717	32398523
Faecaloma	19.76	18.88	15	11271	4741	32497499

Pharmacologic Action:

Source	Code	Description
ATC	N04AC01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers of tropine or tropine derivatives
FDA MoA	N0000000207	Histamine Receptor Antagonists
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	Antimuskarinika
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:66956	antidyskinetic drugs
CHEBI has role	CHEBI:146270	oneirogens
CHEBI has role	CHEBI:149553	anti-coronaviral agents
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175750	Antihistamine

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.64	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.23	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	4.62	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.86	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.16	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.90	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.50	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.89	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.52	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.96	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.93	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	8.55	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.24	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	7.25	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.59	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.69	DRUG MATRIX
Sodium-dependent neutral amino acid transporter B(0)AT1	Transporter	Q695T7	S6A19_HUMAN	INHIBITOR	IC50	4.36	IUPHAR
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.39	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.95	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.85	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.59	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.23	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	5.29	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	6.93	CHEMBL

External reference:

ID	Source
D00778	KEGG_DRUG
132-17-2	SECONDARY_CAS_RN
1424	RXNORM
C0005098	UMLSCUI
CHEBI:3048	CHEBI
CXQ	PDB_CHEM_ID
CHEMBL1201203	ChEMBL_ID
CHEMBL1200383	ChEMBL_ID
DB00245	DRUGBANK_ID
7601	IUPHAR_LIGAND_ID
292	INN_ID
1NHL2J4X8K	UNII
1201549	PUBCHEM_CID
3130	MMSL
4264	MMSL
563	MMSL
d00175	MMSL
001647	NDDF
004667	NDDF
29527005	SNOMEDCT_US
372846002	SNOMEDCT_US
77390008	SNOMEDCT_US
D001590	MESH_DESCRIPTOR_UI
4017824	VANDF
4019630	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9233	INJECTION	1 mg	INTRAMUSCULAR	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8210	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8211	TABLET	1 mg	ORAL	ANDA	16 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8352	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1080	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1081	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1082	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6788	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6789	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6790	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-606	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-607	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-608	TABLET	2 mg	ORAL	ANDA	15 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10858-011	INJECTION	1 mg	INTRAMUSCULAR	ANDA	1 sections
Benztropine Mesylate Injection, USP	HUMAN PRESCRIPTION DRUG LABEL	1	14789-300	INJECTION	1 mg	PARENTERAL	ANDA	11 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-012	INJECTION	1 mg	INTRAVENOUS	NDA authorized generic	16 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-286	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-218	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-219	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-220	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-580	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-707	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-796	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-913	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3116	TABLET	1 mg	ORAL	ANDA	15 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3882	TABLET	2 mg	ORAL	ANDA	13 sections